Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711

J Urol. 2016 Apr;195(4 Pt 1):1172-3. doi: 10.1016/j.juro.2015.11.040. Epub 2016 Jan 16.

Publication types

  • Letter
  • Comment

MeSH terms

  • Erectile Dysfunction*
  • Humans
  • Male
  • Melanoma
  • Phosphodiesterase 5 Inhibitors*
  • Risk
  • Skin Neoplasms

Substances

  • Phosphodiesterase 5 Inhibitors